Fig. 6: BRCA1-I15 is expressed in patient-derived tumors.
From: BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
a Cartoon showing the location of BRCA1 mutations present in PDX models relative to BRCA1 BRCT repeats. See Supplementary Table 2 for more information. b PDX tumors were examined for BRCA1 protein expression using N- or C-terminal-specific antibodies by Western blotting. MDA-MB-231 (231) and SNU-251 (SNU) cells are comparators. c BRCA1 exons 2–3, intron 15, and exons 15–16 mRNA expression in the PDX samples measured by qRT-PCR. MDA-MB-231 (231) and SNU-251 (SNU) cells are included as comparators. d Copy number analyses as described in Fig. 2e. e BRCA1 exons 15–16 reads detected using RNA-seq in PDX221 compared to MDA-MB-231, SNU-251-RR cells. Data are the mean ± SD of n = 3 biological replicates.
